Multiple Sclerosis (MS) is a chronic neuroinflammatory disease characterized by the infiltration of immune cells into central nervous system (CNS) leading to demyelination and ultimately axonal degeneration. Before invading the CNS, immune cells need to cross the bloodbrain barrier (BBB), which normally limits transendothelial leukocyte migration. The BBB is a unique feature of the cerebral vasculature which main function is to maintain the proper homeostasis of the CNS allowing adequate neuronal functioning. The brain endothelium of the BBB possesses specific properties compared to all other endothelial cells in the body. In essence, the BBB is formed by specialized endothelial cells sealed together by intercellular tight junction protein complexes (TJ). BBB dysfunction is a major hallmark of many neurological diseases, including MS. Compromised function of the BBB is also a key early event in the pathogenesis of MS. However, the molecular mechanisms underlying BBB breakdown during MS pathogenesis remain elusive. MicroRNAs (miRNA) are small non-coding RNA molecules containing about 19-25 nucleotides that play a key role in the regulation of gene expression by promoting the degradation of target mRNAs or by inhibiting their translation. Since individual miRNAs are able to down-regulate multiple targets, even small changes in miRNA expression may lead to significant alterations in target protein expression. Using a genomic approach we previously defined a set of miRNAs that is down-regulated both in isolated MS patient brain capillaries and in the human cerebral microvascular endothelial cell line (hCMEC/D3) treated with proinflammatory cytokines, known to impair BBB function. In particular, we found that the miR-30 family, including miR-30a, -30b, -30c, -30d, and -30e, were among the most downregulated miRNAs. In this study, we investigated the effects of the miR-30 family on BBB properties and function. Initial data point towards a protective role of miR-30 family in blood-brain barrier function and the promotion of an immune quiescent phenotype. Our findings suggest that repair of a disturbed BBB through miRNA approach may represent a novel avenue for effective treatment of MS. Focus of this study was the characterization of human T-cell bloodbrain-barrier migration and corresponding molecular trafficking signatures. We examined peripheral blood and cerebrospinal fluid immune cells from patients under long-term anti-VLA-4/natalizumab therapy (LTNT), as well as CNS specimens. LTNT patients' cerebrospinal fluid T cells exhibited healthy central-/effector-memory ratios, but lacked CD49d and showed enhanced MCAM expression. LTNT lead to an increase of PSGL-1 expression on peripheral T cells. While VCAM-1 (VLA-4-receptor) was expressed at all CNS barriers, P-selectin (PSGL-1-receptor) was mainly detected at the choroid plexus. Accordingly, in vitro experiments under physiological flow conditions using primary human endothelial cells and LTNT patients' T cells showed increased PSGL-1-mediated rolling and residual adhesion even under VLA-4-blockade. Adhesion of MCAM + /T H 17 cells was not affected by VLA-4-blocking alone, but was abrogated when both VLA-4 and MCAM were inhibited. Consistent with these data, MCAM + cells were detected in white matter lesions, and in gray matter of MS patients. Our data indicate that lymphocyte trafficking into the CNS under VLA-4 blockade can occur by employing the alternative adhesion molecules, PSGL-1 and MCAM, the latter representing an exclusive pathway for T H 17 cells to migrate over the blood-brain barrier. 
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